Insulin Management for Type 2 Diabetes During Ramadan: A Narrative Review for Clinicians

Article ID: e170522204910 Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Objective: Muslims with insulin-dependent type 2 diabetes are at high risk for adverse events while fasting during the month of Ramadan. However, advances in pharmacologic therapy coupled with creative strategies of insulin administration can mitigate complications. This narrative literature review investigates which insulin subtypes are likely to prevent hypoglycemic events and reduce hyperglycemia during the Ramadan fasting season for this high-risk population.

Design: Narrative literature review

Eligibility Criteria: The following MeSH terms were used: “Diabetes Mellitus, Type 2” and “Insulin,” and the “Text Words”: “Ramadan”, “iftar”, “Muslim fast”, and “religious fast.” The primary focus was on adult, non-pregnant, insulin-dependent type 2 diabetes during Ramadan. Anything beyond this focus was excluded. A total of nine pertinent studies were included for narrative review and analysis.

Information Sources: PubMed, EMBASE and Medline.

Results: The studies identified suggest long-acting insulins reduce the risk of hypoglycemia, and rapid-acting insulin analogues may improve post-iftar hyperglycemia. Moreover, utilizing flexible glycemic targets during Ramadan is a novel strategy that has demonstrated improved outcomes after the fasting season.

Conclusion: Certain insulin subtypes and dosing strategies may be advantageous to use during Ramadan. However, a systematic, comprehensive, and updated review, including a critical appraisal of each original study, is needed to improve clinical care of insulin-dependent type 2 diabetes during Ramadan.

Keywords: Type 2 diabetes mellitus, Islam, insulin, hypoglycemia, hyperglycemia, cultural competency.

[1]
Diabetes Facts & Figures. International Diabetes Federation 2020. [cited 2020 Aug 25]. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
[2]
Diabetes and Ramadan. International Diabetes Federation 2020. [cited 2020 Aug 27]. Available from: https://www.idf.org/our-activities/education/diabetes-and-ramadan.html
[3]
Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: Results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27(10): 2306-11.
[http://dx.doi.org/10.2337/diacare.27.10.2306] [PMID: 15451892]
[4]
Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and the DAR International Alliance 2016. [cited 2020 Aug 27]. Available from: https://www.daralliance.org/daralliance/wp-content/uploads/2018/01/IDF-DAR-Practical-Guidelines_15-April-2016_low.pdf
[5]
Babineaux SM, Toaima D, Boye KS, et al. Multi-country retrospective observational study of the management and outcomes of patients with type 2 diabetes during Ramadan in 2010 (CREED). Diabet Med 2015; 32(6): 819-28.
[http://dx.doi.org/10.1111/dme.12685] [PMID: 25581456]
[6]
Jabbar A, Wan Mohamed WMI, Spaepen E, et al. Fasting experience of patients with type 2 diabetes mellitus on insulin therapy during Ramadan: VISION Ramadan substudy. Diabetes Res Clin Pract 2019; 151: 285-9.
[http://dx.doi.org/10.1016/j.diabres.2019.02.021] [PMID: 30822495]
[7]
Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract 2020; 26(1): 107-39.
[http://dx.doi.org/10.4158/CS-2019-0472] [PMID: 32022600]
[8]
Morales J, Schneider D. Hypoglycemia. Am J Med 2014; 127(10) (Suppl.): S17-24.
[http://dx.doi.org/10.1016/j.amjmed.2014.07.004] [PMID: 25282009]
[9]
Lessan N, Hannoun Z, Hasan H, Barakat MT. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: Insights from Continuous Glucose Monitoring (CGM). Diabetes Metab 2015; 41(1): 28-36.
[http://dx.doi.org/10.1016/j.diabet.2014.11.004] [PMID: 25497966]
[10]
Beshyah SA, Ali KF, Hajjaji IM, et al. Knowledge gaps and perceptions of future research directions on management of diabetes during Ramadan fasting: An online survey of physicians. Diabetes Res Clin Pract 2021; 177108923
[http://dx.doi.org/10.1016/j.diabres.2021.108923] [PMID: 34146601]
[11]
Shehadeh N, Maor Y. Effect of a new insulin treatment regimen on glycaemic control and quality of life of Muslim patients with type 2 diabetes mellitus during Ramadan fast - an open label, controlled, multicentre, cluster randomised study. Int J Clin Pract 2015; 69(11): 1281-8.
[http://dx.doi.org/10.1111/ijcp.12695] [PMID: 26234442]
[12]
Hassanein M, Echtay AS, Malek R, et al. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan. Diabetes Res Clin Pract 2018; 135: 218-26.
[http://dx.doi.org/10.1016/j.diabres.2017.11.027] [PMID: 29183844]
[13]
Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract 2010; 64(8): 1095-9.
[http://dx.doi.org/10.1111/j.1742-1241.2010.02347.x] [PMID: 20337752]
[14]
Kalra S. Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience. Indian J Endocrinol Metab 2016; 20(4): 564-7.
[http://dx.doi.org/10.4103/2230-8210.180644] [PMID: 27366727]
[15]
Soewondo P, Adam JM, Sanusi H, et al. A multicenter, prospective, non-interventional evaluation of efficacy and safety of using biphasic insulin aspart as monotherapy, or in combination with oral hypoglycaemic agent, in the treatment of type 2 diabetic patients before, during & after Ramadan. J Indones Med Assoc 2009; 59: 574-9.
[16]
Hassanein M, Buyukbese MA, Malek R, et al. Real-world safety and effectiveness of insulin glargine 300 U/ml in participants with Type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract 2020; 166108189
[http://dx.doi.org/10.1016/j.diabres.2020.108189]
[17]
Mattoo V, Milicevic Z, Malone JK, et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59(2): 137-43.
[http://dx.doi.org/10.1016/S0168-8227(02)00202-4] [PMID: 12560163]
[18]
Hajjaji IM, Eshwihdi N, Barrowman N. Comparison of analog insulin mix 50:50 with human insulin mix 30:70 in persons with type 2 diabetes during Ramadan. Int J Clin Pract 2019; 73(6)e13348
[http://dx.doi.org/10.1111/ijcp.13348] [PMID: 30912213]
[19]
Altemimi MT, Odhaib SA, Imran HJ, Alhamza A, Almomin A, Mansour AA. Comparison of human premixed and basal plus short-acting insulin regimens for individuals with type 2 diabetes during Ramadan fasting. Cureus 2020; 12(12)e11976
[http://dx.doi.org/10.7759/cureus.11976] [PMID: 33425548]
[20]
Ahmedani MY, Ghafoor E. Achieving safer Ramadan fasting by keeping flexible glycemic targets during the day and tighter targets during the night in insulin treated people with type 2 diabetes. Diabetes Res Clin Pract 2020; 165108234
[http://dx.doi.org/10.1016/j.diabres.2020.108234] [PMID: 32450103]
[21]
Types of Insulin. Diabetes Education Online: Diabetes Teaching Center at the University of California, San Francisco 2020. [cited 2020 Aug 31]. Available from: https://dtc.ucsf.edu/types-of-diabetes/type2/treatment-of-type-2-diabetes/medications-and-therapies/type-2-insulin-rx/types-of-insulin/
[22]
Ibrahim M, Davies MJ, Ahmad E, et al. Recommendations for management of diabetes during Ramadan: Update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Res Care 2020; 8(1)e001248
[http://dx.doi.org/10.1136/bmjdrc-2020-001248] [PMID: 32366501]
[23]
Dabral S, Mukherjee S, Saha N, Manjavkar S, Kohli S. A survey of fasting practices and acceptance of an intervention for achieving control in diabetes during Ramadan. Natl Med J India 2020; 33(1): 5-9.
[http://dx.doi.org/10.4103/0970-258X.308233] [PMID: 33565478]
[24]
Wolfsdorf JI, Garvey KC. Chapter 49 - Management of Diabetes in Children. In: Jameson JL, De Groot LJ, de Krester DM, et al. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia, USA: W.B. Saunders 2016; pp. 854-882.e6.
[http://dx.doi.org/10.1016/B978-0-323-18907-1.00049-4]